-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Pharvaris (NASDAQ:PHVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
Pharvaris (NASDAQ:PHVS) Posts Earnings Results, Beats Expectations By $0.19 EPS
Pharvaris (NASDAQ:PHVS – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.19, MarketWatch Earnings reports.
Pharvaris Trading Down 2.6 %
NASDAQ PHVS opened at $9.07 on Wednesday. The company has a 50-day moving average price of $17.03 and a two-hundred day moving average price of $18.05. Pharvaris has a 52 week low of $8.55 and a 52 week high of $27.50. The stock has a market cap of $288.79 million, a price-to-earnings ratio of -3.49 and a beta of -0.19.
Get Pharvaris alerts:Institutional Investors Weigh In On Pharvaris
A hedge fund recently raised its stake in Pharvaris stock. Bank of America Corp DE boosted its holdings in Pharvaris (NASDAQ:PHVS – Get Rating) by 1,054.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,772 shares of the company's stock after acquiring an additional 5,272 shares during the quarter. Bank of America Corp DE's holdings in Pharvaris were worth $105,000 at the end of the most recent quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have weighed in on PHVS shares. Bank of America cut shares of Pharvaris from a "neutral" rating to an "underperform" rating and dropped their target price for the stock from $26.00 to $13.00 in a report on Monday, August 22nd. SVB Leerink cut their target price on shares of Pharvaris from $25.00 to $20.00 and set an "outperform" rating on the stock in a report on Wednesday. Oppenheimer decreased their target price on Pharvaris from $48.00 to $22.00 and set an "outperform" rating for the company in a research note on Tuesday, August 23rd. Morgan Stanley cut Pharvaris from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $40.00 to $10.00 in a research report on Tuesday, August 23rd. Finally, JMP Securities reduced their price objective on Pharvaris from $34.00 to $18.00 and set a "mkt outperform" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Pharvaris has an average rating of "Hold" and a consensus target price of $16.60.Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Recommended Stories
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
Pharvaris (NASDAQ:PHVS – Get Rating) posted its quarterly earnings results on Monday. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.19, MarketWatch Earnings reports.
納斯達克(股票代碼:PHVS-GET Rating)週一公佈了季度收益報告。MarketWatch收益報告顯示,該公司本季度每股收益(EPS)為0.38美元,比市場普遍預期的每股收益(0.57美元)高出0.19美元。
Pharvaris Trading Down 2.6 %
Pharvaris股價下跌2.6%
NASDAQ PHVS opened at $9.07 on Wednesday. The company has a 50-day moving average price of $17.03 and a two-hundred day moving average price of $18.05. Pharvaris has a 52 week low of $8.55 and a 52 week high of $27.50. The stock has a market cap of $288.79 million, a price-to-earnings ratio of -3.49 and a beta of -0.19.
納斯達克PHV週三開盤報9.07美元。該公司的50日移動均線價格為17.03美元,200日移動均線價格為18.05美元。Pharvaris的52周低點為8.55美元,52周高點為27.50美元。該股市值為2.8879億美元,市盈率為-3.49倍,貝塔係數為-0.19。
Institutional Investors Weigh In On Pharvaris
機構投資者看好Pharvaris
A hedge fund recently raised its stake in Pharvaris stock. Bank of America Corp DE boosted its holdings in Pharvaris (NASDAQ:PHVS – Get Rating) by 1,054.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,772 shares of the company's stock after acquiring an additional 5,272 shares during the quarter. Bank of America Corp DE's holdings in Pharvaris were worth $105,000 at the end of the most recent quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
一家對衝基金最近增持了Pharvaris股票。根據美國銀行在最近提交給美國證券交易委員會(美國證券交易委員會)的文件中,該公司在第一季度將其在Pharvaris(納斯達克:PHV-GET評級)的持股增加了1,054.4%。該公司在本季度額外收購了5272股後,擁有5772股該公司的股票。截至最近一個季度末,美國銀行(Bank Of America Corp DE)持有的Pharvaris股份價值10.5萬美元。70.21%的股票目前由機構投資者和對衝基金持有。
Analyst Ratings Changes
分析師評級發生變化
Pharvaris Company Profile
Pharvaris公司簡介
(Get Rating)
(獲取評級)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Pharvaris N.V.是一家臨牀階段的生物製藥公司,專注於罕見疾病療法的開發和商業化。該公司開發了PHA121,這是一種小分子緩激肽B2受體拮抗劑,目前處於第二階段臨牀試驗,用於治療遺傳性血管性水腫(HAE)。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免費獲取StockNews.com關於Pharvaris(PHV)的研究報告
- 這三份報告將告訴我們許多關於當前經濟的情況。
- 下面的五個是不是打得太高了?
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharvaris Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pharvaris和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧